Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

MONOCLONAL ANTIBODY BASED PRODUCTS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Monoclonal Antibody Based Products in Millions of US$. The major product segments and application areas analyzed are Therapeutics, and Diagnostics, especially for cancer. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of world. Annual forecasts are provided for each region for the period of 2003 through 2015. The report profiles 123 companies including many key and niche players worldwide such as Amgen, Inc., BD Biosciences, Biogen Idec Inc., Biotest AG, CMC ICOS Biologics, Inc., Dendreon Corporation, Elan Corporations Plc, Eli Lilly and Company, Genentech, Inc., Human Genome Sciences, Inc., Immunomedics, Inc., Johnson & Johnson , Centocor, Ortho Biotech Products, L.P., Medarex Inc, Medlmmune Inc, PDL BioPharma, Schering-Plough Corporation, Strategic Diagnostics Inc., UCB Group, and Wyeth Pharmaceuticals. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-3411
Price : $3950
Companies : 123
Pages : 526
Date : October 2008
Market Data Tables : 110

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  MONOCLONAL ANTIBODY BASED PRODUCTS (Complete Report) Pages : 526   | $3950
 
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS4$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Therapeutics.....I-3
  
   Cancer.....I-4
Other Therapeutic Mabs.....I-4
Diagnostics.....I-4
  
II. EXECUTIVE SUMMERY107$2250
  1. Industry Overview.....II-19 $1000  
   Worldwide MAb-Based Products Market: A Profile.....II-1
MAb Market – Set for Significant Growth.....II-1
1$100
   Therapeutic mAb Market – Principal Driving Force.....II-2
Development of New MAbs on a Fast Track.....II-2
1$100
   Genomics Research Leads Way to New Monoclonal Antibodies.....II-3
Bright Outlook for MAbs.....II-3
Current and Future Analysis.....II-3
Regional Perspective.....II-3
1$100
   Product Segment Perspective.....II-4
Competitive Scenario.....II-4
Intensifying Consolidation Activity.....II-4
1$100
   Table 1: Major Acquisitions of Antibody-Focused Companies (2005-2007).....II-5

Table 2: Leading Players in the Worldwide Monoclonal Antibody Therapy Market (2005): Percentage Breakdown of Sales for Genentech/Roche, J & J/Schering Plough, Abbott Laboratories, MedImmune, ImClone/BMS, and Eli Lilly (includes corresponding Graph/Chart).....II-5
1$300
   Table 3: Leading Drugs in the Global Therapeutic Monoclonal Antibodies Market (2006): Percentage Breakdown of Dollar Sales for Remicade, Rituxan, Herceptin, Avastin, Humira, Erbitux, Synagis, Xolair and Others (includes corresponding Graph/Chart).....II-6

Table 4: Monoclonal Antibody Based Products Market (2004): Percentage Breakdown of Leading Manufacturers by Sales for Genentech, Johnson & Johnson, Roche, Abbott, MedImmune, Schering Plough, Eli Lilly, and Others (includes corresponding Graph/Chart).....II-6

Table 5: Monoclonal Antibody Based Products Market (2004): Percentage Breakdown of Leading Drugs by Sales for Remicade, Rituxan, Herceptin, Synagis, Humira, Avastin, ReoPro, Erbitux, Xolair, and Others (includes corresponding Graph/Chart).....II-6
1$300
   Table 6: Leading Products in the Global Oncology Monoclonal Antibodies Market (2008E): Percentage Share Breakdown of Sales for Avastin, Herceptin, Rituxan, Erbitux, and Others (includes corresponding Graph/Chart).....II-7

Table 7: Leading Products in the Global Antibody-Based Anti-Inflammatory Market (2006): Percentage Share Breakdown of Revenues for Enbrel, Remicade, Humira, and Others (includes corresponding Graph/Chart).....II-7
Therapeutic Antibodies in the Market.....II-7
1$300
   Drug Developers Trying to Break the Shackles.....II-8
Rituximab Vs. Epratuzumab.....II-8
1$100
   A Revolution Not too Far.....II-9
Milestones in Development of MAbs.....II-9
Focus on Unmet Medical Needs in the Emerging Markets.....II-9
1$100
  2. Industry Analysis.....II-107 $500  
   Evolution of Monoclonal Antibodies – A Historical Journey.....II-101$100
   Trends and Issues.....II-11
Shift Towards Humanized and Fully Human Antibodies.....II-11
Ageing Baby Boomers Spur MAbs Growth.....II-11
Non-Existent Generic Competition Favors MAb Market.....II-11
1$100
   Partnerships and Collaborations Spark Increase in Profit Margins.....II-12
Pharma Majors & CMOs Augment Investment in Mab Production.....II-12
Rising Number of MAbs Under Clinical Trials.....II-12
1$100
   Select Clinical Trials for Monoclonal Antibodies.....II-131$100
   Major Monoclonal Antibodies in Phase III Trials Across the World.....II-14
High Costs Impede MAbs Penetration.....II-14
1$100
   Opportunities in Technology Development.....II-15
Advancements & Challenges in Antibody Production Processes.....II-15
Increasing Demand for Protein A in Mab Manufacturing.....II-15
1$100
   FCA- A Major Cause for Discomfort in Mice.....II-16
Innovations to Drive Growth in Anti-Ovarian Cancer Drugs Market.....II-16
Rising Incidence of NHL to Drive Monoclonal Antibody Drug Market.....II-16
1$100
  3. Product Overview.....II-176 $600  
   Immune System: Natural Defenders.....II-17
Human Antibodies.....II-17
Antibodies Offer Natural Immunity.....II-17
Induction of The Immune Process.....II-17
Mechanism of Action.....II-17
1$100
   Polyclonal and Monoclonal Antibodies.....II-18
Production of Monoclonal Antibodies.....II-18
Traditional Methods.....II-18
The Hybridoma Technology.....II-18
Separation and Purification of Monoclonals.....II-18
1$100
   Factors Impacting Production of MAbs.....II-19
Types of Monoclonal Antibodies.....II-19
Table 8: Worldwide MAb Market by Product Type (2008): Percentage Share Breakdown for Chimeric, Humanized, Human and Murine (includes corresponding Graph/Chart).....II-19
Murine Monoclonal Antibodies.....II-19
1$300
   Humanized Antibodies/ CDR Grafted Antibodies.....II-20
Murine Vs Human Monoclonal Antibodies.....II-20
1$100
   Chimeric Antibodies: Show Lesser Antigenicity.....II-21
Fully Human Antibodies.....II-21
Bispecific Antibodies.....II-21
Certain Limitations Do Exist.....II-21
1$100
   Advantages of MAbs.....II-22
Advantages and Limitations of MAb Technologies.....II-22
1$100
  4. Diagnostic Applications of Monoclonal Antibodies.....II-233 $300  
   Monoclonal Antibody Based Diagnostics.....II-23
Immunodiagnostics.....II-23
Monoclonals Used as Targeting Agents.....II-23
Radio labeled Monoclonal Antibodies for Diagnostic Imaging.....II-23
1$100
   The Pros and Cons of MAb-Based Immunoconjugates.....II-24
Cytogen: The First to Introduce A Monoclonal Antibody-based Cancer Agent.....II-24
NeoProbe’s Radioimmunogzuided Surgery.....II-24
1$100
   Cancer.....II-25
A Historical Overview.....II-25
Initial Hiccups.....II-25
Tumor Markers.....II-25
1$100
  5. Monoclonal Antibody-Based Therapeutics.....II-268 $700  
   Evolution of Therapeutic Antibody Products.....II-26
Advantages of Therapeutic Monoclonal Antibodies.....II-26
1$100
   Current Scenario in Monoclonal Antibody Therapeutics Market.....II-27
Table 9: Monoclonal Antibody Market by Therapy Area (2004 & 2010): Percentage Breakdown by Sales for Oncology, Arthritis, Immune & Inflammatory Disorders, Infectious Diseases, Cardiovascular, Respiratory, Ophthalmology, and CNS (includes corresponding Graph/Chart).....II-27
1$300
   Cancer Therapeutics.....II-28
Monoclonal Antibodies Offer Hope Against Cancer.....II-28
Monoclonal Antibodies Approved For Cancer Treatment in the World.....II-28
1$100
   Monoclonal Antibody Cancer Therapies Under Development.....II-29
Antibody Therapies for Cancer.....II-29
1$100
   Cancer: A Serious Issue and Plaguing Illness Worldwide.....II-30
Breast Cancer: The Most Common Form of Cancer in American Women.....II-30
Breast Cancer - Treatment Options.....II-30
1$100
   Monoclonal Antibodies Against NHL.....II-31
Monoclonal Antibodies Against Ovarian Cancer.....II-31
MAb Immunotherapy – Effective for Residual Ovarian Cancer.....II-31
Melanoma.....II-31
1$100
   Immunologic Effector Functions.....II-32
Colorectal Cancer: Rising Incidence.....II-32
Panorex: The First Cancer Therapeutic in the Market.....II-32
Myeloid Leukemia.....II-32
2$200
  6. Other Therapeutic Monoclonal Antibodies.....II-349 $600  
   Therapeutic Monoclonal Antibody Drugs and Applications.....II-34
MAbs used in Clinical Field.....II-34
Inflammation Therapeutics.....II-34
Inflammation.....II-34
1$100
   Asthma: A Chronic Affliction.....II-35
Autoimmune Diseases.....II-35
What Goes Wrong.....II-35
1$100
   Intervention Better Than Prevention.....II-36
Some Autoimmune Diseases.....II-36
Multiple Sclerosis.....II-36
1$100
   Crohn’s Disease.....II-37
Rheumatoid Arthritis.....II-37
Organ Transplantation.....II-37
Biology of Transplantation.....II-37
Types of Transplants.....II-37
Autografts.....II-37
1$100
   Syngeneic Transplants.....II-38
Allografts.....II-38
Xenografts.....II-38
Follow-up Treatment.....II-38
Products to Counter Rejection.....II-38
OKT3: A Monoclonal Already in the Market.....II-38
1$100
   Infectious Diseases.....II-39
Sepsis .....II-39
A Rapid Process.....II-39
Gram Negative Bacteria are the Causative Agents.....II-39
1$100
   A Retrospect.....II-40
Monoclonal Antibodies and Septic Shock.....II-40
HIV/AIDS.....II-40
What is AIDS?.....II-40
1$100
   Global Statistics.....II-41
HIV/AIDS Testing.....II-41
Monoclonal Antibodies and HIV.....II-41
Cardiovascular.....II-41
Cardiovascular Diseases are Fatal.....II-41
1$100
   Treatment Options.....II-42
Causes of Cardiovascular Diseases.....II-42
ReoPro.....II-42
1$100
  7. Regulations Impacting the Industry.....II-432 $200  
   Regulations in the US.....II-43
Approval: A Laborious Process.....II-43
Clinical Trials.....II-43
1$100
   Orphan Drug Status.....II-44
1$100
  8. Research and Development Activities.....II-452 $200  
   Rituxan and Herceptin from Genentech.....II-45
FuCell hybridomas.....II-45
Test-tube MAbs/ Phase Display Library.....II-45
Rituxan for Cancer Treatment.....II-45
1$100
   GenMAb Develops Fully Human Antibodies.....II-46
Protein Design Labs Licenses Trioma.....II-46
Protein Design Labs’ Innovative Technology.....II-46
1$100
  9. Product Launches and Developments.....II-473 $300  
   Amgen Introduces Vectibix.....II-47
Trevigen Introduces Mouse Monoclonal Antibody.....II-47
UCB Receives FDA Approval for Cimzia®.....II-47
GSK’s Tykerb Receives FDA Approval.....II-47
1$100
   Dr. Reddy’s Introduces Reditux™.....II-48
Morphotek Receives Orphan Drug Status for MORAb - 009 mAb.....II-48
Biocon Introduces BIOMab Monoclonal Antibody.....II-48
Biotest AG and AERES Biomedical Develop BT-062.....II-48
Genentech Launches Avastin.....II-48
Biotest Unveils Intratect®.....II-48
1$100
   Genentech Introduces Xolair.....II-49
Genentech Unveils Raptiva.....II-49
Corixa Presents BEXXAR.....II-49
IGEN Launches Monoclonal Antibody Therapies.....II-49
MAb Against Pseudomonas Aeruginosa.....II-49
Wyeth Introduces Mylotarg.....II-49
1$100
  10. Recent Industry Activity.....II-5025 $1400  
   EUSA Pharma to Take Over Cytogen.....II-50
AVANIR Inks a Definitive Agreement to Divest Anthrax Antibodies.....II-50
1$100
   Access Pharmaceuticals Acquires Somanta Pharmaceuticals.....II-51
Daiichi Sankyo to Take Over U3 Pharma.....II-51
IMUC Completes Molecular Antibody Technology Acquisition.....II-51
Callisto Merger Corporation Merges with Celldex Therapeutics.....II-51
1$100
   Genmab Enters into Antibody Research Collaboration with Pepscan.....II-52
BTI Enters into an Agreement with Raven.....II-52
Arana and Kyowa Hakko Sign Agreement to Jointly Develop ART 104.....II-52
1$100
   Eusa Sells Antibody Research Business.....II-53
CG Therapeutics and UoW Agree for Joint Monoclonal Antibody Program.....II-53
Raven and CMC ICOS Collaborate to Advance RAV18.....II-53
SDI to Develop mAbs for SAIC-F and NCI.....II-53
1$100
   HGS Reacquires Rights for TRAIL Receptor Antibodies.....II-54
CAT Grants Exclusive Worldwide License of CAT-213 to iCo.....II-54
Morphotek and HMI in Licensing Agreement.....II-54
Amgen Enters into Licensing Agreement with Kyowa Hakko.....II-54
1$100
   Dyax and Sanofi-Aventis Sign Agreements.....II-55
HGS Enters into Antibody Collaboration Agreement with Xencor.....II-55
1$100
   CSL Limited Inks a Collaboration Agreement with Celltrion.....II-56
Eisai Acquires Morphotek.....II-56
1$100
   Astellas US Holding Takes Over Agensys.....II-57
Astrazeneca Creates New Integrated Business Unit – Medimmune.....II-57
1$100
   Genentech Acquires Tanox.....II-58
Biotest Acquires Assets of Nabi Biologics.....II-58
CMC Acquires ICOS Biologics Operation.....II-58
Roche Takes Over THP.....II-58
1$100
   GTC and LFB Commence CD20 Monoclonal Antibody Development.....II-59
Regeneron Grants a Non-Exclusive License to AstraZeneca.....II-59
OncoMed Enters into Monoclonal Antibody Deal with GSK.....II-59
1$100
   BioArctic and Eisai Announce Licensing Agreement.....II-60
MediGene Collaborates with Celltrion.....II-60
Amgen Inks Collaboration and License Pact with Daiichi Sankyo.....II-60
CMC Biopharmaceuticals Inks Agreement with Morphotek.....II-60
1$100
   CMC Biopharmaceuticals Inks Agreement with Biotest.....II-61
Eli Lilly Collaborates with MacroGenics.....II-61
Genentech Inks Global Licensing Agreement with Seattle Genetics.....II-61
VaxGen to Merge with Raven Biotechnologies.....II-61
1$100
   Abeome Enters into Distribution Agreement with Millipore.....II-62
Compugen Forays into Monoclonal Antibody Business.....II-62
MilleGen and LFB Enter into Partnership Agreement.....II-62
1$100
   Favrille Acquires Diversa’s Anti-CD20 Monoclonal Antibodies.....II-63
Kirin Inks Licensing Agreement with Astellas Pharma.....II-63
Viropro in Partnership with NRC-BRI.....II-63
1$100
   Merck Acquires Abmaxis.....II-64
Micromet Merges with CancerVax.....II-64
Tanabe & Janssen Team Up to Develop Anti-TNF Alpha Monoclonal Antibody.....II-64
Intercell Enters into Strategic Alliance with Kirin.....II-64
1$100
   Xencor Extends R&D Collaboration with Roche.....II-65
MedImmune Inks Licensing Agreement with Japan Tobacco.....II-65
Immunomedics Enters into an Agreement with UCB for Epratuzumab.....II-65
1$100
   Akorn and Serum Institute Enter into Development and Distribution Agreement.....II-66
FDA Clears IND for CYT-500 Monoclonal Antibody from Cytogen.....II-66
LSP Acquires Global License for Monoclonal Antibodies from Ludwig Institute.....II-66
1$100
   Seattle Genetics in Agreement with Laureate to Manufacture Monoclonal Antibody Drug
  Candidates.....II-67
EU Grants Orphan Drug Designation to GPC’s Anticancer Monoclonal Antibody.....II-67
1$100
   Laureate Collaborates with Bradmer on Neuradiab Monoclonal Antibody for Cancer
  Treatment.....II-68
Amgen Takes Over Abgenix.....II-68
Celera and Medarex in Strategic Alliance for Developing Human Monoclonal Antibody
  Therapeutics.....II-68
UCB Collaborates with Immunomedics.....II-68
1$100
   Crucell Collaborates with DSM for Monoclonal Antibody Licensing Business.....II-69
Roche Licenses Rabbit Monoclonal Antibody Technology from Epitomics.....II-69
BioGenex Receives FDA Pre-Market Approval for InSite™ Monoclonal Antibody.....II-69
Upstate Bags Marketing Rights for Anti-ZAP-70 Monoclonal Antibody.....II-69
1$100
   XOMA Bags NIAID Contract to Develop Anti-Botulinum Neurotoxin Monoclonal
  Antibodies.....II-70
HGS Bags Two-Phase Contract for ABthrax™ Mab from the US Government.....II-70
Medarex and PharmAthene Receive Funding for Development of Valortim™.....II-70
1$100
   UCB Collaborates with Millenium.....II-71
MorphoSys Acquires Two Antibody Technology Companies.....II-71
Tanabe Seiyaku and Remicade Sign Addendum.....II-71
Abgenix Receives Royalty from Human Genome.....II-71
Amgen Acquires Tularik.....II-71
Sunesis Pharmaceuticals Collaborates with Biogen Idec.....II-71
1$100
   H3 Pharma Inc. Enters into a Manufacturing Agreement with DSM Biologics.....II-72
EMBL and Abnova Inks Collaboration Agreement.....II-72
AstraZeneca and CAT in Five-Year Strategic Alliance for Monoclonal Antibody
  Research.....II-72
UCB Acquires Celltech.....II-72
1$100
   ImmunoGen Signs Licensing Agreement with Biogen.....II-73
Lonza Inks MAbs Manufacturing and Supply Agreement with NovImmune.....II-73
Avanir and Peregrine Sign License Agreement.....II-73
BioVest Concludes Agreement with Bioventix.....II-73
Roche to Set Up Two Manufacturing Facilities in Switzerland.....II-73
XTL Biopharm Bags European patent for Human Monoclonal Anti Body.....II-73
1$100
   MBL and Medarex Bags FDA approval for CDA-1 Phase I Trials.....II-74
Health Canada Approves HUMIRA.....II-74
1$100
  11. Industry Activity in the Recent Past (2000-2003).....II-756 $600  
   CAT Signs Licensing Agreement with Micromet.....II-75
CAT Enters into Agreement with Genzyme.....II-75
Medarex and Avlon Enter into Agreement.....II-75
Micromet, Enzon and CAT Sign Cross-License Agreement.....II-75
Xerion and CAT Enter into Agreement.....II-75
Genetastix and Nissho Enter into Agreement.....II-75
1$100
   InNexus and Corixa Enter into Agreement.....II-76
Abbott Collaborates with LigoCyte.....II-76
CAT Acquires Drug Royalty Corporation.....II-76
CAT and Amrad Join Hands for Research.....II-76
IDEC's Receives FDA Approval for Zevalin.....II-76
Medarex Enters into Research Alliance with Seattle Genetics.....II-76
1$100
   Dow, Epicyte and Centocor Join Forces to Develop Monoclonal Antibody.....II-77
Eos, Medarex and Biosite in Alliance for Cancer Treatment.....II-77
Imgenex forms Alliance with GMO.....II-77
CAT and Elan Enter into Strategic Alliance.....II-77
Bioinvent International Enters into Agreement with Novo Nordisk for Drug Discovery
  Research.....II-77
1$100
   Epicyte and Dow Chemical Enter into Agreement.....II-78
Rockland Announces the Completion of Laboratory Expansion.....II-78
Roche’s MAbThera Receives Approval in Japan.....II-78
Aviva Launches Manufacturing and Marketing Operations.....II-78
ICOS and Seattle Enters into Joint Development and Manufacturing Agreement.....II-78
Medarex and Corixa Team-up to Develop Human Monoclonal Antibodies.....II-78
Taisho Enters into Research Alliance with IDEC.....II-78
1$100
   PDL Signs Agreement with InterMune.....II-79
ProMetic Signs Agreement with Integrated Protein.....II-79
Medarex Signs Agreement with ZynloGenetics.....II-79
CAT Joins Hands with GD. Searle.....II-79
Medarex and MedImmune Enter into Antibody Research Agreement.....II-79
Lonza Signs Agreement with ImClone Systems.....II-79
1$100
   MedImmune and Alkermes Enter into Agreement.....II-80
GTC and Abgenix Enter into Production Agreement.....II-80
Genzyme Transgenics Expands Agreement with Centocor.....II-80
PDL and InterMune Enter into an Agreement.....II-80
1$100
  12. Focus on Select Global Players.....II-8110 $700  
   Amgen, Inc. (US).....II-81
BD Biosciences (US).....II-81
1$100
   Biogen Idec Inc (US).....II-82
Biotest AG (Germany).....II-82
1$100
   CMC ICOS Biologics, Inc......II-83
Dendreon Corporation (US).....II-83
Elan Corporations Plc (Ireland).....II-83
1$100
   Eli Lilly and Company (US).....II-84
Genentech, Inc. (US).....II-84
1$100
   Human Genome Sciences, Inc. (US).....II-85
Immunomedics, Inc. (US).....II-85
1$100
   Johnson & Johnson (US).....II-86
Centocor (US).....II-86
1$100
   Ortho Biotech Products, L.P. (US).....II-87
Medarex, Inc. (US).....II-87
MedImmune, Inc. (US).....II-87
1$100
   PDL BioPharma (US).....II-88
Schering-Plough Corporation (US).....II-88
1$100
   Strategic Diagnostics Inc (US).....II-89
UCB Group (Belgium).....II-89
Wyeth Pharmaceuticals (US).....II-89
2$200
  13. Global Market Perspective.....II-91   
   Table 10: World Recent Past, Current & Future Market Analysis for Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-911$300
   Table 11: World Long-term Projections for Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-921$300
   Table 12: World 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-931$300
   Table 13: World Recent Past, Current & Future Market Analysis for Therapeutic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-941$300
   Table 14: World Long-term Projections for Therapeutic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-951$300
   Table 15: World 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-961$300
   Table 16: World Long-term Projections for Therapeutic Monoclonal Antibody Based Products by Segment – Cancer and Other Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-97

Table 17: World Long-term Projections for Therapeutic Monoclonal Antibody Based Products by Segment – Cancer and Other Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-97
1$300
   Table 18: World 10-Year Perspective for Therapeutic Monoclonal Antibody Based Products by Segments – Percentage Breakdown of Dollar Sales for Cancer and Other Therapeutics Markets for Years 2003, 2008 & 2012.....II-981$300
   Table 19: World Recent Past, Current & Future Market Analysis for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-991$300
   Table 20: World Long-term Projections for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1001$300
   Table 21: World 10-Year Perspective for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-1011$300
   Table 22: World Recent Past, Current & Future Market Analysis for Other Therapeutic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-1021$300
   Table 23: World Long-term Projections for Other (*) Therapeutic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1031$300
   Table 24: World 10-Year Perspective for Other (*) Therapeutic Monoclonal Antibody Based Products by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-1041$300
   Table 25: World Recent Past, Current & Future Market Analysis for Diagnostic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-1051$300
   Table 26: World Long-term Projections for Diagnostic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1061$300
   Table 27: World 10-Year Perspective for Diagnostic Monoclonal Antibody Based Products by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-1071$300
III. MARKET76$1950
  1. The United States.....III-133 $1375  
   A. Market Analysis.....III-1
Global Hub of MAbs.....III-1
Approved Therapeutic Antibodies in the US (as of 2007).....III-1
1$75
   Therapeutic Monoclonal Antibodies Market – An Overview.....III-2
New Heights for US Cancer Therapeutics.....III-2
Competitive Landscape.....III-2
1$75
   Leading Products.....III-3
Table 28: Leading Products in the US Therapeutic Monoclonal Antibodies Market (2007): Percentage Breakdown of Revenues for Remicade, Avastin, Rituxan, Herceptin, Synagis, Lucentis, Erbitux, and Others (includes corresponding Graph/Chart).....III-3
1$150
   Table 29: Leading Players in the US Therapeutic Monoclonal Antibodies Market (2007): Percentage Share Breakdown of Revenues for Genentech Inc, Centocor, MedImmune, Bristol Meyer's Squibb, Amgen, Hoffman-La Roche, and Others (includes corresponding Graph/Chart).....III-4
Focus on Key Players.....III-4
Amgen, Inc......III-4
1$150
   BD Biosciences.....III-5
Biogen Idec Inc.....III-5
1$75
   CMC ICOS Biologics, Inc......III-6
Dendreon Corporation.....III-6
1$75
   Eli Lilly and Company.....III-7
Genentech, Inc......III-7
Human Genome Sciences.....III-7
1$75
   Immunomedics.....III-81$75
   Johnson & Johnson.....III-9
Centocor.....III-9
Ortho Biotech Products, L.P......III-9
Medarex, Inc......III-9
1$75
   MedImmune, Inc.....III-101$75
   PDL BioPharma.....III-11
Schering-Plough Corporation.....III-11
Strategic Diagnostics Inc.....III-11
1$75
   Wyeth Pharmaceuticals.....III-12
Product launches.....III-12
2$150
   Strategic Developments.....III-1418$825
   B. Market Analytics.....III-32
Table 30: US Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-32
1$150
   Table 31: US Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-33

Table 32: US 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-33
1$150
  2. Canada.....III-343 $225  
   A. Market Analysis.....III-34
Strategic Developments.....III-34
1$75
   B. Market Analytics.....III-35
Table 33: Canadian Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment –Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-35

Table 34: Canadian Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-35
1$150
   Table 35: Canadian 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-36
1$150
  3. Japan.....III-375 $375  
   A. Market Analysis.....III-37
Strategic Developments.....III-37
3$225
   B. Market Analytics.....III-40
Table 36: Japanese Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment –Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010, (includes corresponding Graph/Chart).....III-40

Table 37: Japanese Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-40
1$150
   Table 38: Japanese 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-41
1$150
  4. Europe.....III-427 $625  
   A. Market Analysis.....III-42
Biotechnology and Pharmacy Research.....III-42
Monoclonal Antibody-Based Products Market in Europe.....III-42
European Therapeutic MAbs Market – An Overview.....III-42
Approved Therapeutic Antibodies in Europe as of 2004.....III-42
1$75
   Need to Reduce Complexities, Time & Cost of mAb Development.....III-43
Information Dissemination – Critical for Enhancing mAb Sales.....III-43
Monoclonal Antibody Immunotherapy for NHL.....III-43
MabThera – A Dominant MAb Drug in Europe.....III-43
1$75
   Emerging Radioimmunotherapy Products.....III-44
Challenges for New Drug Development.....III-44
1$75
   B. Market Analytics.....III-45
Table 39: European Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Geographic Region – France, Germany, Italy, UK & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-45

Table 40: European Long-term Projections for Monoclonal Antibody Based Products by Geographic Region – France, Germany, Italy, UK & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-45
1$150
   Table 41: European Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-46

Table 42: European Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-46
1$150
   Table 43: European 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region –Percentage Breakdown of Dollar Sales for France, Germany, Italy, The UK, and Rest of Europe for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-471$150
   Table 44: European 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-48
1$150
  4a. France.....III-494 $325  
   A. Market Analysis.....III-49
Strategic Developments.....III-49
2$150
   B. Market Analytics.....III-51
Table 45: French Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment –Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-51

Table 46: French Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-51
1$150
   Table 47: French 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-52
1$150
  4b. Germany.....III-535 $375  
   A. Market Analysis.....III-53
Biotest AG- A Key Player.....III-53
Product Launches.....III-53
1$75
   Strategic Developments.....III-542$150
   B. Market Analytics.....III-56
Table 48: German Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment –Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-56

Table 49: German Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-56
1$150
   Table 50: German 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-57
1$150
  4c. Italy.....III-583 $350  
   Market Analysis.....III-58
Table 51: Italian Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment –Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-58
1$150
   Table 52: Italian Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-591$150
   Table 53: Italian 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-60
1$150
  4d. The United Kingdom.....III-615 $375  
   A. Market Analysis.....III-61
Monoclonal Antibodies Market – An Overview.....III-61
Strategic Developments.....III-61
2$150
   Product Launches.....III-631$75
   B. Market Analytics.....III-64
Table 54: UK Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment –Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-64

Table 55: UK Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-64
1$150
   Table 56: UK 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-65
1$150
  4e. Rest of Europe.....III-667 $550  
   A. Market Analysis.....III-66
Key Players.....III-66
Elan Corporations Plc (Ireland).....III-66
UCB Group (Belgium).....III-66
1$75
   Strategic Developments.....III-673$225
   B. Market Analytics.....III-70
Table 57: Rest of Europe Market for Monoclonal Antibody Based Products – Recent Past, Current & Future Analysis by Product Segment for Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-70
1$150
   Table 58: Rest of Europe Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-711$150
   Table 59: Rest of Europe 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-72
1$150
  5. Rest of World.....III-734 $450  
   A. Market Analysis.....III-73
Australia.....III-73
India.....III-73
Strategic Developments.....III-73
2$150
   B. Market Analytics.....III-75
Table 60: Rest of World Market for Monoclonal Antibody Based Products – Recent Past, Current & Future Analysis by Product Segment for Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-75

Table 61: Rest of World Market for Monoclonal Antibody Based Products – Long-term Projections by Product Segment for Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-75
1$150
   Table 62: Rest of World 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-761$150
IV. COMPETITIVE LANDSCAPE 327$995
  
Total Companies Profiled: 123 (including Divisions/Subsidiaries - 144)

Region/Country                 Players


The United States                 89 
Canada                             6
Japan                              6
Europe                            33
     France                        5
     Germany                       7
     The United Kingdom            6
     Italy                         1
     Spain                         1
     Rest of Europe               13
Asia-Pacific (Excluding Japan)     9
Middle-East                        1
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign